0000000000249503

AUTHOR

A. Di Costanzo

showing 4 related works from this author

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

2005

Objective: To measure white matter (WM) and gray matter (GM) atrophy and lesion load in a large population of patients with multiple sclerosis (MS) using a fully automated, operator-independent, multiparametric segmentation method. Methods: The study population consisted of 597 patients with MS and 104 control subjects. The MRI parameters were abnormal WM fraction (AWM-f), global WM-f (gWM-f), and GM fraction (GM-f). Results: Significant differences between patients with MS and control subjects included higher AWM-f and reduced gWM-f and GM-f. MRI data showed significant differences between patients with relapsing-remitting and secondary progressive forms of MS. Significant correlations bet…

AdultMalePathologymedicine.medical_specialtyAdolescentBrain mappingNerve Fibers MyelinatedCentral nervous system diseaseWhite matterMultiple sclerosisAtrophySex FactorsPredictive Value of TestsNeural PathwaysmedicineHumansAge of OnsetMultiple Sclerosis/physiopathologyAgedCross-Sectional StudieBrain MappingExpanded Disability Status Scalemedicine.diagnostic_testBrain/physiopathologybusiness.industryMultiple sclerosisBrainMagnetic resonance imagingInterferon-betaMiddle Agedmedicine.diseasePrognosislesion loadMagnetic Resonance ImagingMultiple Sclerosis/diagnosimedicine.anatomical_structureCross-Sectional Studiesmultiple sclerosiLinear ModelsDisease ProgressionEducational StatusFemaleNeurology (clinical)Age of onsetAtrophybusinessMultiple Sclerosis/complicationbrain atrophyMRI
researchProduct

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study

2009

Background To investigate in a large cohort of patients with multiple sclerosis (MS), lesion load and atrophy evolution, and the relationship between clinical and magnetic resonance imaging (MRI) correlates of disease progression. Methods Two hundred and sixty-seven patients with MS were studied at baseline and two years later using the same MRI protocol. Abnormal white matter fraction, normal appearing white matter fraction, global white matter fraction, gray matter fraction and whole brain fraction, T2-hyperintense, and T1-hypointense lesions were measured at both time points. Results The majority of patients were clinically stable, whereas MRI-derived brain tissue fractions were signifi…

AdultMalePathologymedicine.medical_specialtyAdolescentCentral nervous systemmultiple sclerosisSeverity of Illness IndexLesion loadWhite matterCentral nervous system diseaseYoung AdultDegenerative diseaseAtrophyMultiple Sclerosis Relapsing-RemittingatrophyRisk FactorsT2 lesionsmedicinefollow upHumansAgedmedicine.diagnostic_testbusiness.industryMultiple sclerosisBrain AtrophyBrainMagnetic resonance imagingMiddle AgedMultiple Sclerosis Chronic Progressivelesion loadmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureCross-Sectional StudiesLogistic ModelsNeurologymultiple sclerosiMultivariate AnalysisDisease ProgressionFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesMRI
researchProduct

Central action of cinnarizine and flunarizine: A saccadic eye movement study

1994

The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single oral dose of FZ (20 mg) and CZ (150 mg) on CNS function by means of computer analysis of SEM. Ten healthy volunteers were studied according to a double-blind, cross-over, placebo-controlled design. Peak saccadic velocity (PSV), which is related to the function of a specific group of burst neurons located in the brain stem, was significantly reduced by FZ. No significant effect of …

AdultCentral Nervous SystemMaleCinnarizineCentral nervous systemAdministration OralCinnarizinePlacebosDouble-Blind MethodmedicineSaccadesHumansPharmacology (medical)FlunarizinePharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryEye movementCalcium Channel BlockersSaccadic maskingElectrophysiologymedicine.anatomical_structureMechanism of actionSaccadeNeurology (clinical)medicine.symptombusinessNeuroscienceFlunarizinemedicine.drug
researchProduct

Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

2006

This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up per…

medicine.medical_specialtyNeurologyMultiple SclerosisDermatologySeverity of Illness IndexInterferon beta • Multiple sclerosis • Phase IV • Odds ratioInternal medicineSeverity of illnessmedicineConfidence IntervalsHumansImmunologic FactorsMultiple sclerosiNeuroradiologyAnalysis of Variancemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingGeneral MedicineOdds ratioInterferon-betaOdds ratiomedicine.diseaseInterferon betaMagnetic Resonance ImagingConfidence intervalPsychiatry and Mental healthItalyPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)NeurosurgeryPhase IVbusinessFollow-Up Studies
researchProduct